View Financial HealthEOM Pharmaceuticals Holdings 배당 및 자사주 매입배당 기준 점검 0/6EOM Pharmaceuticals Holdings 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jan 07EOM Pharmaceutical Holdings, Inc. Reports Promising Preclinical Results and Provides an Update on EOM613 and EOM147EOM Pharmaceutical Holdings, Inc. provided an update on its preclinical programs in 2025 and its planned clinical activities in 2026 for its two lead product candidates EOM613 and EOM147. In 2025, the company completed IND-enabling toxicological and dosing preclinical animal studies for EOM613 with favorable results. In addition, no adverse effects were seen in tissue upon histopathological testing. Based on these data, combined with previously reported promising results of Phase I/IIa 2023 human clinical trial in hospitalized COVID-19 patients with cytokine-driven respiratory inflammation in Brazil, the company planning an initial Phase II exploratory clinical trial in patients with Crohn's disease. This trial is designed to include 15-20 patients and will be conducted at clinical sites in New Brunswick and Lakewood, NJ, under Principal Investigator Arkady Broder, MD, Director of Gastroenterology at the St. Peter's Healthcare System. The trial will enroll subjects with moderate to severe Crohn's disease who have failed or could not tolerate at least one conventional therapy. EOM anticipates initiating the trial in the first quarter 2026 to test for signs of clinical remission and endoscopic remission with EOM613 treatment and to measure biomarkers such as C-reactive protein, calprotectin and pro-inflammatory serum cytokines. In addition, based on these preclinical results, EOM plans to reactivate an Investigational New Drug (IND) application for the treatment of cachectic cancer patients at the FDA's Office of Oncologic Diseases (OOD) with a view to conducting an open-label Phase II trial with Stage 4 cancer patients. The trial's Principal Investigator is Azriel Hirschfeld, MD, at Hirschfeld Oncology in Brooklyn, NY, an expert in the treatment of gastrointestinal cancer patients with advanced disease who typically progress to a cachectic condition. In previous clinical trials in AIDS, cancer cachexia and COVID-19 patients, EOM613 treatment was well-tolerated, even in very sick patients. A broad-spectrum immune regulating agent that regulates pro-and anti-inflammatory cytokines in patients without the risk of severe side effects associated with the use of antibody or corticosteroid drugs could be beneficial in the treatment of Crohn's disease and ulcerative colitis.공시 • Sep 08EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in BrazilEOM Pharmaceutical Holdings, Inc. announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil. This exploratory Phase 1/2a clinical trial (NCT05212532), designated RESCUE, was a proof-of-concept, open-label study evaluating the safety, tolerability, and preliminary efficacy measures, such as the effects on serum cytokines, when EOM613 was added to the standard-of-care therapy. The trial included two cohorts of patients hospitalized for COVID-19: one cohort was in the intensive care unit (ICU) and the other cohort was not (non-ICU). The study was conducted at four different medical centers in the Brazilian states of Sao Paolo and Goaia. The trial was originally designed to enroll a total of 40 patients – 20 in each cohort. The trial was redesigned, however, due to challenges in patient enrollment during the COVID-19 pandemic as a result of Brazil's successful vaccination program which led to a reduction in eligible hospitalized patients. The redesigned trial enrolled a total of 23 patients eligible for evaluation. The study's Principal Investigator was Florentino Cardoso Filho, MD, at the Casa de Saude Hospital in Campinas, Sao Paolo, and former President of the Brazilian Medical Association.공시 • Aug 03EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock공시 • Jun 25ImmunoCellular Therapeutics, Ltd. has filed an IPO in the amount of $25 million.ImmunoCellular Therapeutics, Ltd. has filed an IPO in the amount of $25 million. Security Name: Common Stock Security Type: Common Stock지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 IMUC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: IMUC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장EOM Pharmaceuticals Holdings 배당 수익률 vs 시장IMUC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (IMUC)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Biotechs)2.5%분석가 예측 (IMUC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 IMUC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 IMUC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 IMUC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: IMUC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/18 07:26종가2026/06/18 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스EOM Pharmaceuticals Holdings, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jan 07EOM Pharmaceutical Holdings, Inc. Reports Promising Preclinical Results and Provides an Update on EOM613 and EOM147EOM Pharmaceutical Holdings, Inc. provided an update on its preclinical programs in 2025 and its planned clinical activities in 2026 for its two lead product candidates EOM613 and EOM147. In 2025, the company completed IND-enabling toxicological and dosing preclinical animal studies for EOM613 with favorable results. In addition, no adverse effects were seen in tissue upon histopathological testing. Based on these data, combined with previously reported promising results of Phase I/IIa 2023 human clinical trial in hospitalized COVID-19 patients with cytokine-driven respiratory inflammation in Brazil, the company planning an initial Phase II exploratory clinical trial in patients with Crohn's disease. This trial is designed to include 15-20 patients and will be conducted at clinical sites in New Brunswick and Lakewood, NJ, under Principal Investigator Arkady Broder, MD, Director of Gastroenterology at the St. Peter's Healthcare System. The trial will enroll subjects with moderate to severe Crohn's disease who have failed or could not tolerate at least one conventional therapy. EOM anticipates initiating the trial in the first quarter 2026 to test for signs of clinical remission and endoscopic remission with EOM613 treatment and to measure biomarkers such as C-reactive protein, calprotectin and pro-inflammatory serum cytokines. In addition, based on these preclinical results, EOM plans to reactivate an Investigational New Drug (IND) application for the treatment of cachectic cancer patients at the FDA's Office of Oncologic Diseases (OOD) with a view to conducting an open-label Phase II trial with Stage 4 cancer patients. The trial's Principal Investigator is Azriel Hirschfeld, MD, at Hirschfeld Oncology in Brooklyn, NY, an expert in the treatment of gastrointestinal cancer patients with advanced disease who typically progress to a cachectic condition. In previous clinical trials in AIDS, cancer cachexia and COVID-19 patients, EOM613 treatment was well-tolerated, even in very sick patients. A broad-spectrum immune regulating agent that regulates pro-and anti-inflammatory cytokines in patients without the risk of severe side effects associated with the use of antibody or corticosteroid drugs could be beneficial in the treatment of Crohn's disease and ulcerative colitis.
공시 • Sep 08EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in BrazilEOM Pharmaceutical Holdings, Inc. announced the results of its completed clinical trial in hospitalized COVID-19 patients with severe symptoms treated with its investigational immune-regulating drug product EOM613. The trial was conducted in Brazil. This exploratory Phase 1/2a clinical trial (NCT05212532), designated RESCUE, was a proof-of-concept, open-label study evaluating the safety, tolerability, and preliminary efficacy measures, such as the effects on serum cytokines, when EOM613 was added to the standard-of-care therapy. The trial included two cohorts of patients hospitalized for COVID-19: one cohort was in the intensive care unit (ICU) and the other cohort was not (non-ICU). The study was conducted at four different medical centers in the Brazilian states of Sao Paolo and Goaia. The trial was originally designed to enroll a total of 40 patients – 20 in each cohort. The trial was redesigned, however, due to challenges in patient enrollment during the COVID-19 pandemic as a result of Brazil's successful vaccination program which led to a reduction in eligible hospitalized patients. The redesigned trial enrolled a total of 23 patients eligible for evaluation. The study's Principal Investigator was Florentino Cardoso Filho, MD, at the Casa de Saude Hospital in Campinas, Sao Paolo, and former President of the Brazilian Medical Association.
공시 • Aug 03EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million. Security Name: Common Stock Security Type: Common Stock
공시 • Jun 25ImmunoCellular Therapeutics, Ltd. has filed an IPO in the amount of $25 million.ImmunoCellular Therapeutics, Ltd. has filed an IPO in the amount of $25 million. Security Name: Common Stock Security Type: Common Stock